Mr. Timothy Ko reports

ENTHEON BIOMEDICAL ANNOUNCES SHARE CONSOLIDATION

Entheon Biomedical Corp.'s board of directors has approved a consolidation of all of the company's issued and outstanding common shares on the basis of one postconsolidated share for every 10 preconsolidated shares.

After giving effect to the consolidation, the company will have 5,908,926 common shares issued and outstanding. The company's name and stock symbol shall remain the same.

The consolidation remains subject to the approval of the Canadian Securities Exchange. The company will issue a further news release announcing the effective date on which the company will commence trading on a consolidated basis.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.